1. [CASE 1 — QUESTION 1]
A 57-year-old man with chronic-phase chronic myeloid leukemia (CML) has been treated with imatinib for four years and achieved a sustained major molecular response (MMR; BCR-ABL1 transcript at or below 0.1% on the international scale). Over two consecutive quantitative PCR measurements three months apart, his BCR-ABL1 transcript level rises from 0.04% to 0.6%, and he has now lost his major molecular response. He reports good adherence and is taking no new interacting medications. His oncologist is considering a change in therapy. What is the most appropriate next step before selecting a new agent?
A) Empirically switch to a second-generation tyrosine kinase inhibitor (TKI) without further testing, since any second-generation agent will overcome the resistance
B) Increase the imatinib dose and recheck the transcript level in six months
C) Perform BCR-ABL1 kinase-domain mutation analysis, because the specific resistance mutation present determines which agent will be effective, and detection of certain mutations (notably T315I) excludes whole classes of TKIs
D) Refer immediately for allogeneic stem cell transplantation as the only effective option for imatinib resistance
ANSWER: C
Rationale:
Option C is correct. When a patient loses major molecular response on a TKI with confirmed adherence and no interacting drugs, BCR-ABL1 kinase-domain mutation analysis must be performed before switching, because the specific mutation governs which agent will work. In particular, detection of the T315I gatekeeper mutation excludes imatinib and all second-generation agents and mandates ponatinib or asciminib, so empiric switching without mutation data risks continued failure.
Option A: Option A is incorrect. Empiric switching to a second-generation TKI without mutation analysis is the classic error; if T315I is present, no second-generation agent will work.
Option B: Option B is incorrect. Confirmed loss of major molecular response with good adherence signals resistance that warrants mutation analysis and a change in strategy, not simple dose escalation with a long delay.
Option D: Option D is incorrect. Effective pharmacologic options remain depending on the mutation; transplant is reserved for advanced-phase or specific high-risk settings and is not the immediate next step in chronic phase before mutation testing.
2. [CASE 1 — QUESTION 2]
Continuing with the same patient. Kinase-domain mutation analysis returns the T315I gatekeeper mutation. His history includes peripheral arterial disease and a myocardial infarction two years ago. Which therapeutic choice best balances efficacy against this patient's vascular risk?
A) Asciminib, which is active against T315I through its allosteric mechanism and avoids the dose-dependent arterial occlusive risk that makes ponatinib particularly hazardous in a patient with established vascular disease
B) Dasatinib, accepting its risk of pleural effusion as preferable to other toxicities
C) Nilotinib, whose greater potency overcomes the T315I mutation
D) Bosutinib, which combines SRC and ABL inhibition to bypass T315I
ANSWER: A
Rationale:
Option A is correct. T315I restricts effective therapy to the two agents active against it: ponatinib and asciminib. In a patient with peripheral arterial disease and prior myocardial infarction, ponatinib's dose-dependent arterial occlusive events make it especially dangerous, so asciminib — active against T315I at the higher dose and carrying a different toxicity profile — is the better-matched choice.
Option B: Option B is incorrect. Dasatinib does not have reliable activity against T315I, so it would fail to control the resistant clone regardless of its toxicity profile.
Option C: Option C is incorrect. Nilotinib does not overcome T315I and itself carries arterial occlusive and QTc risks, making it doubly inappropriate here.
Option D: Option D is incorrect. Bosutinib's dual SRC/ABL inhibition does not confer activity against T315I.
3. [CASE 1 — QUESTION 3]
Continuing with the same patient. He is started on asciminib. A trainee asks why asciminib remains active against T315I when the second-generation ATP-competitive agents do not. Which explanation is correct?
A) Asciminib is given at such high concentrations that it overwhelms the T315I mutation by mass action at the ATP site
B) Asciminib is a STAMP inhibitor that binds the allosteric myristoyl pocket of ABL1 rather than the ATP-binding site, locking the kinase in an inactive conformation, so mutations within the ATP pocket such as T315I do not block its binding
C) Asciminib chemically reverses the T315I substitution, restoring the normal threonine residue
D) Asciminib inhibits transcription of the BCR-ABL1 fusion gene, so the specific kinase-domain mutation is irrelevant
ANSWER: B
Rationale:
Option B is correct. Asciminib is a STAMP inhibitor (Specifically Targeting the ABL Myristoyl Pocket). It binds the allosteric myristoyl pocket on the C-terminal lobe of the ABL1 kinase domain and locks the kinase in an inactive conformation. Because its binding does not depend on the ATP pocket, ATP-pocket mutations such as T315I — which defeat ATP-competitive agents — do not block asciminib.
Option A: Option A is incorrect. Asciminib's T315I activity comes from binding a different (allosteric) site, not from overwhelming the ATP site by sheer concentration.
Option C: Option C is incorrect. Asciminib does not chemically revert the mutation; it inhibits the mutant kinase allosterically.
Option D: Option D is incorrect. Asciminib acts on the existing kinase protein at the myristoyl pocket; it does not suppress transcription of the fusion gene.
4. [CASE 1 — QUESTION 4]
Continuing with the same patient. He tolerates asciminib well, and the team plans his monitoring schedule. Which monitoring is most specifically directed at asciminib's characteristic adverse effects?
A) Serial echocardiography for pleural effusion every two months
B) Frequent electrocardiograms targeting a corrected QT interval below 450 ms after each dose change
C) High-resolution chest CT surveillance for early-onset pulmonary toxicity in the first week
D) Blood pressure monitoring and serum lipase measurement, because asciminib is characteristically associated with hypertension, thrombocytopenia, and pancreatic enzyme elevation
ANSWER: D
Rationale:
Option D is correct. Asciminib's characteristic adverse effects include hypertension, thrombocytopenia, and pancreatic enzyme elevation, so blood pressure monitoring and serum lipase measurement (along with blood counts) are the targeted surveillance for this agent.
Option A: Option A is incorrect. Pleural effusion and its echocardiographic/imaging surveillance are characteristic of dasatinib, not asciminib.
Option B: Option B is incorrect. Concentration-dependent QTc prolongation with serial ECGs is the nilotinib monitoring requirement, not asciminib's.
Option C: Option C is incorrect. Early-onset pulmonary toxicity in the first week is the distinctive event of brigatinib (an ALK inhibitor), not asciminib.
5. [CASE 2 — QUESTION 5]
A 63-year-old woman with chronic-phase CML is treated with nilotinib. At a follow-up visit she mentions that she takes each dose with a substantial breakfast "so it does not upset my stomach." She has no symptoms currently. Why is this administration habit a genuine safety concern rather than a minor preference?
A) Food chemically inactivates nilotinib in the stomach, so each dose taken with breakfast is completely wasted
B) A high-fat meal increases nilotinib exposure by approximately 80%, and because nilotinib prolongs the QT interval in a concentration-dependent manner, dosing with food can raise the plasma level into a range that lengthens the QTc and risks a ventricular arrhythmia
C) Food causes nilotinib to be eliminated unchanged by the kidneys before it can act, producing subtherapeutic levels
D) Food has no meaningful effect on nilotinib; the only concern is gastric irritation
ANSWER: B
Rationale:
Option B is correct. Taking nilotinib with food, particularly a high-fat meal, increases its exposure by roughly 80%. Because nilotinib's QTc-prolonging effect is concentration-dependent, a food-boosted plasma level lengthens the QTc further and raises the risk of a dangerous ventricular arrhythmia. This is precisely why the label requires strict fasting — no food for at least 2 hours before and 1 hour after each dose.
Option A: Option A is incorrect. Food increases absorption rather than inactivating the drug; the danger is too much drug, not a wasted dose.
Option C: Option C is incorrect. Food raises nilotinib exposure; it does not divert the drug to rapid renal elimination or cause subtherapeutic levels.
Option D: Option D is incorrect. Food has a major effect on nilotinib exposure with real arrhythmic consequences, so it is far more than a gastric-irritation issue.
6. [CASE 2 — QUESTION 6]
Continuing with the same patient. Her nilotinib dose is increased for a suboptimal response. A surveillance electrocardiogram one week later shows a corrected QT interval (QTc) of 495 ms, up from a baseline of 432 ms. She is counseled to resume strict fasting. Regarding the nilotinib itself, what is the most appropriate immediate action based on this QTc value?
A) Hold nilotinib, because a QTc above the roughly 480 ms threshold requires withholding the drug; also review for other QTc-prolonging medications and correct any electrolyte abnormalities before cautious resumption
B) Continue nilotinib at the increased dose and repeat the electrocardiogram in three months
C) Increase the nilotinib dose further to accelerate the molecular response, since the QTc change is incidental
D) Permanently discontinue all BCR-ABL TKI therapy, as any QTc prolongation precludes future TKI use
ANSWER: A
Rationale:
Option A is correct. Nilotinib should be held when the QTc exceeds approximately 480 ms; a value of 495 ms meets that threshold. The appropriate steps are to hold the drug, review concomitant medications for other QTc-prolonging agents, and correct any electrolyte abnormalities (potassium, magnesium) before cautious resumption — alongside the fasting correction already made.
Option B: Option B is incorrect. A QTc of 495 ms requires holding the drug now; continuing at the higher dose with delayed monitoring is unsafe.
Option C: Option C is incorrect. Increasing the dose would raise the concentration and worsen the concentration-dependent QTc prolongation, the opposite of what is required.
Option D: Option D is incorrect. QTc prolongation is managed by holding and correcting reversible factors, then cautious resumption or a switch; it does not categorically preclude all future TKI therapy.
7. [CASE 2 — QUESTION 7]
Continuing with the same patient. After her nilotinib is restarted at an adjusted dose with documented fasting and a normalized QTc, she returns several months later reporting new calf pain with walking that resolves with rest, and her ankle-brachial index is reduced. Which complication of nilotinib does this presentation most likely represent?
A) Pleural effusion from fluid retention
B) Drug-induced interstitial lung disease
C) Pulmonary arterial hypertension
D) Peripheral arterial occlusive disease, part of nilotinib's recognized vascular toxicity that also includes ischemic cardiovascular events
ANSWER: D
Rationale:
Option D is correct. New intermittent claudication with a reduced ankle-brachial index indicates peripheral arterial occlusive disease, which is a recognized vascular toxicity of nilotinib along with ischemic cardiovascular events. This vascular risk is a defining safety concern of the drug and warrants vascular evaluation and reassessment of continued therapy.
Option A: Option A is incorrect. Pleural effusion presents with dyspnea and a pleural fluid collection, not exertional calf pain with a reduced ankle-brachial index, and is characteristic of dasatinib.
Option B: Option B is incorrect. Interstitial lung disease presents with dyspnea and diffuse pulmonary opacities, not lower-extremity claudication.
Option C: Option C is incorrect. Pulmonary arterial hypertension presents with dyspnea and right-heart findings, not peripheral claudication, and is more associated with dasatinib.
8. [CASE 2 — QUESTION 8]
Continuing with the same patient. After the vascular evaluation, a decision is made to keep her on a different agent, but a trainee asks about a laboratory finding seen earlier when she was on nilotinib: an isolated rise in total bilirubin that was predominantly unconjugated (indirect), with normal transaminases. How should this finding be interpreted?
A) It indicates fulminant hepatocellular failure requiring immediate drug discontinuation and transplant evaluation
B) It reflects biliary obstruction and mandates urgent endoscopic retrograde cholangiopancreatography
C) Nilotinib commonly causes an indirect (unconjugated) hyperbilirubinemia through inhibition of the conjugating enzyme UGT1A1, which is generally benign; the key is to distinguish it from true hepatocellular injury, which would show a rising direct (conjugated) bilirubin and elevated transaminases
D) It is diagnostic of hemolysis and requires transfusion
ANSWER: C
Rationale:
Option C is correct. Nilotinib inhibits the conjugating enzyme UGT1A1, producing an indirect (unconjugated) hyperbilirubinemia in a substantial proportion of patients. This is generally benign, analogous to a Gilbert-type pattern. The clinically important step is distinguishing it from genuine hepatocellular injury, which would manifest as a rising direct (conjugated) bilirubin together with elevated transaminases.
Option A: Option A is incorrect. An isolated indirect hyperbilirubinemia with normal transaminases is not fulminant hepatic failure and does not warrant transplant evaluation.
Option B: Option B is incorrect. Biliary obstruction produces a conjugated (direct) hyperbilirubinemia with cholestatic enzyme elevations, not an isolated indirect rise with normal transaminases.
Option D: Option D is incorrect. While hemolysis can raise indirect bilirubin, the characteristic and far more likely explanation here is nilotinib-induced UGT1A1 inhibition; there is no indication for transfusion.
9. [CASE 3 — QUESTION 9]
A 52-year-old never-smoker is diagnosed with metastatic lung adenocarcinoma. Comprehensive molecular profiling shows an EGFR exon 19 deletion. Staging brain MRI reveals several small, asymptomatic brain metastases, and she has no neurologic deficits. Which first-line systemic therapy is most appropriate?
A) Osimertinib, because its high central nervous system (CNS) penetration controls the asymptomatic brain metastases as well as systemic disease, often allowing upfront whole-brain radiation and its neurocognitive sequelae to be deferred
B) Gefitinib, a first-generation EGFR TKI, reserving osimertinib until the T790M resistance mutation emerges
C) Platinum-doublet chemotherapy, because the presence of brain metastases precludes targeted therapy
D) Crizotinib, which has the best CNS penetration among targeted agents regardless of the driver
ANSWER: A
Rationale:
Option A is correct. For an EGFR exon 19 deletion patient with asymptomatic brain metastases, osimertinib is the preferred first-line agent because of its exceptional CNS penetration: it achieves high CNS response rates and can serve as initial management of brain disease, allowing upfront whole-brain radiation — and its neurocognitive harms — to be deferred. It is also the first-line standard for systemic disease.
Option B: Option B is incorrect. Osimertinib is preferred over first-generation agents first-line and has far superior CNS penetration; waiting for T790M forgoes that benefit.
Option C: Option C is incorrect. Brain metastases do not preclude targeted therapy in an EGFR-mutant tumor; an EGFR TKI is preferred over upfront chemotherapy.
Option D: Option D is incorrect. Crizotinib is an ALK/ROS1 inhibitor with poor CNS penetration and no role in EGFR-mutant disease.
10. [CASE 3 — QUESTION 10]
Continuing with the same patient. Two weeks after starting osimertinib she develops a papulopustular (acneiform) rash over her face and upper chest and is worried the drug is harming her or failing. How should this be interpreted and managed?
A) The rash is an allergic hypersensitivity reaction requiring permanent discontinuation of osimertinib
B) The rash signals tumor resistance and warrants an immediate switch of therapy
C) The rash is an on-target effect of EGFR inhibition in the skin and a marker that the drug is engaging its target; it is associated with better outcomes rather than failure, so osimertinib should be continued while the rash is managed with topical measures and, if needed, an oral tetracycline-class antibiotic
D) The rash indicates the drug is no longer reaching the tumor and the osimertinib dose should be increased substantially
ANSWER: C
Rationale:
Option C is correct. The acneiform rash arises from on-target inhibition of EGFR in the skin — the same action exerted on the tumor — so it is an expected pharmacologic effect, not failure or allergy, and a more pronounced rash is associated with better outcomes. Management is to continue the drug while treating the rash with topical care and, for more troublesome rash, an oral tetracycline-class antibiotic such as doxycycline. (Osimertinib generally causes less severe rash than first-generation agents because it spares wild-type EGFR, but the on-target mechanism is the same.)
Option A: Option A is incorrect. The rash is a predictable on-target effect, not an allergic reaction, and does not require permanent discontinuation.
Option B: Option B is incorrect. The rash marks drug activity at its target, not resistance, so an immediate switch is unjustified.
Option D: Option D is incorrect. The rash shows the drug is engaging EGFR; a large dose increase is inappropriate and would worsen toxicity.
11. [CASE 3 — QUESTION 11]
Continuing with the same patient. After 18 months on osimertinib she develops rapid clinical decline with new bulky liver metastases and a sharply rising LDH. A plasma circulating tumor DNA (ctDNA) panel is uninformative, showing no actionable resistance alteration. What is the most appropriate next diagnostic step?
A) Restart a first-generation EGFR TKI, since osimertinib resistance reliably reverts to a T790M-driven, gefitinib-sensitive state
B) Perform a tissue rebiopsy, because resistance to first-line osimertinib is mechanistically heterogeneous (including C797S, MET and HER2 amplification, and histologic transformation to small cell lung cancer in roughly 15% of cases), an uninformative plasma result does not exclude these mechanisms, and the aggressive picture raises concern for transformation, which only tissue can diagnose
C) Continue osimertinib unchanged and repeat imaging in three months
D) Begin empiric MET-inhibitor therapy, presuming MET amplification without further testing
ANSWER: B
Rationale:
Option B is correct. Resistance to first-line osimertinib has no single dominant mechanism — it spans tertiary EGFR mutations (C797S), bypass-pathway amplifications (MET, HER2), and histologic transformation to small cell lung cancer in about 15% of cases. A negative or uninformative plasma ctDNA result does not exclude these, and small cell transformation can be diagnosed only on tissue, which the aggressive clinical picture (bulky visceral disease, rising LDH) further supports. Tissue rebiopsy is therefore the correct next step.
Option A: Option A is incorrect. Post-osimertinib resistance is heterogeneous and does not predictably revert to a first-generation-sensitive T790M state.
Option C: Option C is incorrect. Clear progression indicates an operative resistance mechanism; an uninformative plasma test does not mean none exists, and watchful waiting is unsafe given the decline.
Option D: Option D is incorrect. Empiric MET-inhibitor therapy without confirming the mechanism is inappropriate when several distinct mechanisms — including transformation — are possible and tissue can distinguish them.
12. [CASE 3 — QUESTION 12]
Continuing with the same patient. The tissue rebiopsy does not show transformation; instead, molecular testing identifies a tertiary EGFR C797S mutation in addition to T790M and the original exon 19 deletion. The oncologist explains that the spatial relationship of C797S to T790M determines treatability. Which statement correctly describes this relationship?
A) C797S restores wild-type EGFR function and eliminates the oncogenic driver, so no further therapy is needed
B) C797S is identical to the BCR-ABL1 T315I mutation and is overcome by ponatinib
C) The cis-versus-trans relationship is irrelevant; C797S has the same treatment implication regardless of configuration
D) C797S prevents osimertinib from forming its covalent bond; when C797S is in cis with T790M (and del19) the tumor is resistant to all approved EGFR TKIs, whereas when C797S is in trans with T790M a combination of a first-generation EGFR TKI plus osimertinib can overcome the resistance
ANSWER: D
Rationale:
Option D is correct. C797S substitutes the cysteine residue that osimertinib needs to form its covalent bond, so the drug can no longer covalently anchor to the kinase. The configuration relative to T790M is decisive: when C797S and T790M are in cis on the same allele (alongside del19), the tumor is resistant to all approved EGFR TKIs; when they are in trans on separate alleles, a combination of a first-generation EGFR TKI plus osimertinib can overcome the resistance.
Option A: Option A is incorrect. C797S is a resistance mutation, not a reversion to wild-type function; the driver is not eliminated.
Option B: Option B is incorrect. Although both are drug-binding-site resistance mutations, C797S is an EGFR mutation not addressed by ponatinib (a BCR-ABL1 agent).
Option C: Option C is incorrect. The cis-versus-trans configuration is exactly what determines treatability, so it is far from irrelevant.
13. [CASE 4 — QUESTION 13]
A 60-year-old woman with EGFR-mutant (L858R) NSCLC is being treated with erlotinib in a setting where osimertinib is not available. Three weeks into therapy she develops a moderate (grade 2) acneiform rash involving the face, scalp, and upper chest, with discomfort but no systemic symptoms. What is the most appropriate management of the rash?
A) Permanently discontinue erlotinib, since a grade 2 rash indicates an unacceptable allergic reaction
B) Continue erlotinib and treat the grade 2 rash with an oral tetracycline-class antibiotic (doxycycline or minocycline) plus topical measures, reserving dose reduction for grade 3 to 4 rash
C) Hold erlotinib indefinitely until the rash resolves completely, then resume at the same dose
D) Switch immediately to chemotherapy, since the rash signals treatment failure
ANSWER: B
Rationale:
Option B is correct. The acneiform rash is an on-target EGFR effect, and management follows a graded ladder: grade 1 with topical agents; grade 2 with an oral tetracycline-class antibiotic (doxycycline or minocycline) plus topical care while continuing the drug; and dose reduction reserved for grade 3 to 4. A grade 2 rash is therefore treated without stopping erlotinib.
Option A: Option A is incorrect. The rash is a predictable on-target effect, not an allergic reaction, and grade 2 does not warrant permanent discontinuation.
Option C: Option C is incorrect. Indefinitely holding the drug for a manageable grade 2 rash is unnecessary and interrupts effective therapy; oral antibiotics plus topical care allow continuation.
Option D: Option D is incorrect. The rash reflects drug activity, not failure, so switching to chemotherapy is unwarranted.
14. [CASE 4 — QUESTION 14]
Continuing with the same patient. After 14 months of good response, surveillance imaging shows new and enlarging pulmonary lesions consistent with progression. She remains clinically stable. What is the most appropriate next diagnostic step to guide therapy?
A) Test for the EGFR T790M resistance mutation, using plasma circulating tumor DNA (ctDNA) as the preferred, least invasive first approach, and proceed to tissue rebiopsy only if the plasma result is uninformative
B) Switch empirically to chemotherapy without molecular testing, since resistance mechanisms cannot guide therapy
C) Obtain an immediate surgical lung biopsy as the only acceptable way to assess resistance
D) Increase the erlotinib dose, presuming the progression reflects inadequate drug exposure
ANSWER: A
Rationale:
Option A is correct. The most common acquired resistance mechanism to a first-generation EGFR TKI is T790M. The preferred workup is to test for T790M using plasma circulating tumor DNA first, because it is the least invasive approach; if the plasma result is uninformative (a negative plasma result does not exclude the mutation), tissue rebiopsy follows.
Option B: Option B is incorrect. Resistance testing does guide therapy here — a detected T790M directs osimertinib — so abandoning testing forfeits an effective option.
Option C: Option C is incorrect. Plasma ctDNA, not upfront surgical biopsy, is the preferred first test; tissue biopsy is reserved for uninformative plasma results.
Option D: Option D is incorrect. Progression after a prolonged response reflects acquired resistance (commonly T790M), not inadequate exposure, so a dose increase is not the appropriate step.
15. [CASE 4 — QUESTION 15]
Continuing with the same patient. Plasma circulating tumor DNA testing detects the original L858R mutation together with a newly acquired T790M mutation. Which is the most appropriate next therapy?
A) Increase the erlotinib dose to overcome T790M
B) Add afatinib to erlotinib, as the combination overcomes T790M
C) Switch to osimertinib, the third-generation EGFR TKI specifically active against the T790M-mutant receptor while relatively sparing wild-type EGFR
D) Switch to crizotinib, since acquired resistance indicates the tumor is now ALK-driven
ANSWER: C
Rationale:
Option C is correct. Detection of T790M at progression directs therapy to osimertinib, which was designed to inhibit the EGFR receptor carrying both the sensitizing mutation and T790M while relatively sparing wild-type EGFR. This is the standard response to a T790M-positive result.
Option A: Option A is incorrect. T790M is a binding-altering resistance mutation, not a problem of inadequate exposure, so dose escalation will not restore control.
Option B: Option B is incorrect. Afatinib does not overcome T790M, and combining it with erlotinib does not address the mutation.
Option D: Option D is incorrect. The tumor remains EGFR-driven with added T790M; it has not become ALK-driven, so crizotinib is inappropriate.
16. [CASE 4 — QUESTION 16]
Continuing with the same patient. Before starting osimertinib, the oncologist orders a specific baseline cardiac study because of an agent-specific toxicity of osimertinib. Which toxicity is this baseline assessment intended to detect, and what is its proposed mechanism?
A) Pleural effusion, from fluid retention typical of this agent
B) Pulmonary arterial hypertension, from remodeling of the pulmonary vasculature
C) Peripheral arterial occlusive disease, from accelerated atherosclerosis
D) A reduction in left ventricular ejection fraction (and QTc prolongation), thought to reflect off-target inhibition of ErbB4 in cardiomyocytes, for which baseline echocardiography is recommended with follow-up assessment for cardiac symptoms or signs
ANSWER: D
Rationale:
Option D is correct. Osimertinib can cause a reduction in left ventricular ejection fraction, thought to reflect off-target inhibition of ErbB4 in cardiomyocytes, along with QTc prolongation. Baseline echocardiography is recommended, with repeat assessment if cardiac symptoms or signs develop, making it the agent-specific cardiac surveillance for osimertinib.
Option A: Option A is incorrect. Pleural effusion is the signature toxicity of dasatinib, not osimertinib, and would not be assessed by baseline echocardiography for LVEF.
Option B: Option B is incorrect. Pulmonary arterial hypertension is more associated with dasatinib and is not the osimertinib-specific concern driving baseline echocardiography.
Option C: Option C is incorrect. Peripheral arterial occlusive disease is characteristic of nilotinib and ponatinib, not osimertinib, and is not assessed by echocardiography.
17. [CASE 5 — QUESTION 17]
A 44-year-old never-smoker is diagnosed with metastatic lung adenocarcinoma, and molecular testing reveals an ALK rearrangement (EML4-ALK fusion). Staging brain MRI shows several asymptomatic brain metastases. Which first-line ALK inhibitor is most appropriate, and why?
A) Crizotinib, because it was the first ALK inhibitor approved and its CNS penetration is more than adequate for brain metastases
B) Imatinib, because its broad kinase activity covers ALK-rearranged disease
C) Alectinib, a CNS-penetrant second-generation ALK inhibitor that achieves high brain concentrations, controls and delays CNS progression, and produces markedly longer progression-free survival than crizotinib as first-line therapy — making it preferable when brain metastases are present
D) Osimertinib, because it has the best CNS penetration of any targeted agent regardless of the driver mutation
ANSWER: C
Rationale:
Option C is correct. In a treatment-naive ALK-positive patient with brain metastases, a CNS-penetrant second-generation agent such as alectinib is preferred: it reaches high CNS concentrations, treats and delays CNS progression, overcomes most crizotinib-resistance mutations, and yields substantially longer progression-free survival than crizotinib as first-line therapy. The brain metastases make CNS penetration the decisive selection factor.
Option A: Option A is incorrect. Crizotinib penetrates the CNS poorly, making it a worse choice when brain metastases are present; prior approval date does not justify selecting an inferior agent.
Option B: Option B is incorrect. Imatinib targets BCR-ABL1/KIT/PDGFRA, not the ALK fusion, and has no role in ALK-positive NSCLC.
Option D: Option D is incorrect. Osimertinib targets EGFR-mutant disease; despite its CNS penetration, it is not indicated for an ALK-driven tumor.
18. [CASE 5 — QUESTION 18]
Continuing with the same patient. Suppose instead she had initially been treated with crizotinib (in a resource-limited setting) and after 10 months her thoracic and abdominal disease remained well controlled, but new brain metastases appeared on surveillance imaging while she remained neurologically asymptomatic. How should this pattern be interpreted and managed?
A) This represents systemic treatment failure, so ALK-directed therapy should be abandoned for palliative chemotherapy
B) This is the expected crizotinib failure mode — crizotinib penetrates the CNS poorly while ALK-positive disease is prone to brain metastasis, producing isolated CNS progression despite systemic control — and the appropriate move is to switch to a CNS-penetrant ALK inhibitor such as alectinib or lorlatinib
C) This indicates a second primary brain tumor unrelated to the lung cancer, so the ALK diagnosis should be questioned
D) The crizotinib dose should simply be doubled to force more drug across the blood-brain barrier
ANSWER: B
Rationale:
Option B is correct. Crizotinib penetrates the CNS poorly, while ALK-positive NSCLC has a strong propensity for brain metastasis; together these produce isolated CNS progression while systemic disease stays controlled — the characteristic crizotinib failure mode, not failure of ALK-directed therapy as a strategy. The correct response is to switch to a CNS-penetrant ALK inhibitor (alectinib or lorlatinib).
Option A: Option A is incorrect. Systemic disease is controlled, so this is not systemic treatment failure, and chemotherapy discards an effective targeted strategy.
Option C: Option C is incorrect. CNS progression here is the expected behavior of the known ALK-positive tumor under a poorly penetrant drug, not a separate primary tumor.
Option D: Option D is incorrect. Doubling crizotinib does not reliably overcome its intrinsic poor CNS penetration; switching to a CNS-penetrant agent is the rational solution.
19. [CASE 5 — QUESTION 19]
Continuing with the same patient. She is switched to a CNS-penetrant agent and later progresses; testing reveals the ALK G1202R solvent-front mutation, and she is started on lorlatinib. Which statement best describes lorlatinib's relevant activity and the monitoring its characteristic toxicities require?
A) Lorlatinib is a third-generation ALK inhibitor active against the G1202R solvent-front mutation with excellent CNS penetration; its characteristic toxicities are CNS effects (cognitive and mood changes) and near-universal hypercholesterolemia, so neuropsychiatric symptom assessment and fasting lipid monitoring are required
B) Lorlatinib is a first-generation agent whose main limitation is poor CNS penetration, so brain imaging is unnecessary
C) Lorlatinib's signature toxicity is pleural effusion, so echocardiographic surveillance is the priority
D) Lorlatinib is an EGFR inhibitor, so monitoring should focus on acneiform rash and diarrhea
ANSWER: A
Rationale:
Option A is correct. Lorlatinib is a third-generation ALK inhibitor designed to overcome second-generation resistance, including the G1202R solvent-front mutation, and it has excellent CNS penetration. Its characteristic toxicities are CNS adverse effects (cognitive impairment and mood changes) and hypercholesterolemia that develops in nearly all patients, so monitoring includes neuropsychiatric symptom assessment at visits and fasting lipid panels, with statin therapy commonly required.
Option B: Option B is incorrect. Lorlatinib is third-generation with excellent CNS penetration, not a poorly penetrant first-generation agent.
Option C: Option C is incorrect. Pleural effusion is the signature toxicity of dasatinib, not lorlatinib.
Option D: Option D is incorrect. Lorlatinib targets ALK (and ROS1), not EGFR, so rash and diarrhea are not its characteristic toxicities.
20. [CASE 5 — QUESTION 20]
Continuing with the same patient, who is 38 years old and of childbearing potential. She uses a combined oral contraceptive pill. Given that lorlatinib induces CYP3A4 and that the ALK TKI class is teratogenic, what is the correct contraceptive counseling?
A) No contraception is needed, because lorlatinib itself prevents pregnancy
B) The combined oral contraceptive remains fully reliable, so no change is required
C) She should double her oral contraceptive dose, which fully compensates for the interaction
D) Because lorlatinib induces CYP3A4 and accelerates breakdown of hormonal contraceptives, the pill may fail; since the drug is teratogenic, she must use a reliable non-hormonal method such as a copper intrauterine device or another non-hormonal barrier approach during therapy
ANSWER: D
Rationale:
Option D is correct. Two facts combine: lorlatinib induces CYP3A4 and thereby speeds the metabolism of hormonal contraceptives, reducing their reliability, and the ALK TKI class is teratogenic. A hormonal method therefore cannot be trusted, so a reliable non-hormonal method — a copper intrauterine device or another non-hormonal barrier method — is required during therapy to prevent a pregnancy the drug could harm.
Option A: Option A is incorrect. Lorlatinib does not prevent pregnancy; it can harm a fetus, which is exactly why reliable contraception is required.
Option B: Option B is incorrect. CYP3A4 induction reduces the reliability of the combined oral contraceptive, so it is not fully reliable here.
Option C: Option C is incorrect. Simply doubling a hormonal dose is not a recommended, dependable solution to enzyme induction; a non-hormonal method is advised.
21. [CASE 6 — QUESTION 21]
A 47-year-old never-smoker is diagnosed with metastatic lung adenocarcinoma. Next-generation sequencing identifies a ROS1 fusion (CD74-ROS1). She has no brain metastases at diagnosis. Which first-line targeted option is appropriate for ROS1-rearranged disease?
A) Entrectinib or crizotinib, both of which have substantial activity against ROS1 fusions, with entrectinib offering superior CNS penetration as an approved first-line option
B) Osimertinib, since ROS1 and EGFR share an identical kinase domain and respond to the same drugs
C) Imatinib, because its broad kinase activity includes ROS1 fusions
D) Nilotinib, which is the standard first-line agent for ROS1-rearranged NSCLC
ANSWER: A
Rationale:
Option A is correct. ROS1 fusions are targetable, and both crizotinib and entrectinib have substantial first-line activity; entrectinib is an approved first-line option with superior CNS penetration compared to crizotinib. Either is an appropriate ROS1-directed first-line choice, with the CNS-penetration advantage favoring entrectinib when brain coverage is a priority.
Option B: Option B is incorrect. ROS1 and EGFR are distinct kinases with distinct inhibitors; osimertinib is EGFR-directed and has no role against ROS1 fusions.
Option C: Option C is incorrect. Imatinib targets BCR-ABL1/KIT/PDGFRA, not ROS1 fusions, and is not used for ROS1-positive NSCLC.
Option D: Option D is incorrect. Nilotinib is a BCR-ABL1 agent with no role in ROS1-rearranged disease.
22. [CASE 6 — QUESTION 22]
Continuing with the same patient. She is treated with crizotinib and responds for about 18 months, then develops radiographic progression. Repeat molecular testing identifies a newly acquired ROS1 G2032R solvent-front mutation. Which agent is most appropriate for this acquired resistance?
A) A higher dose of crizotinib, since G2032R reflects insufficient drug exposure
B) Osimertinib, which targets the kinase domain shared by ROS1 and EGFR
C) Repotrectinib, a next-generation ROS1 inhibitor with demonstrated activity against the ROS1 G2032R solvent-front mutation, the dominant resistance mechanism after a prior ROS1 TKI
D) Nilotinib, which overcomes solvent-front mutations across kinase families
ANSWER: C
Rationale:
Option C is correct. The ROS1 G2032R solvent-front mutation is the dominant acquired resistance mechanism after a prior ROS1 TKI such as crizotinib, and repotrectinib is a next-generation ROS1 inhibitor specifically active against G2032R, making it the appropriate choice for this resistance.
Option A: Option A is incorrect. G2032R is a binding-altering resistance mutation, not a problem of inadequate exposure, so dose escalation of crizotinib will not restore control.
Option B: Option B is incorrect. Osimertinib is EGFR-directed; ROS1 and EGFR are distinct kinases, and osimertinib has no activity against ROS1 G2032R.
Option D: Option D is incorrect. Nilotinib is a BCR-ABL1 agent and does not address ROS1 solvent-front resistance.
23. [CASE 6 — QUESTION 23]
Continuing with the same patient, who is now responding to repotrectinib. She is diagnosed with active tuberculosis, and the infectious disease team proposes a rifampin-based regimen. Like other agents in these kinase-inhibitor families, her TKI is a CYP3A4 substrate, and rifampin is a strong CYP3A4 inducer. What is the most appropriate management?
A) Proceed with rifampin and make no change, since the interaction is clinically negligible
B) Recognize that rifampin will strongly induce CYP3A4 and substantially lower the TKI's exposure, risking loss of cancer control; in consultation with infectious disease, use a non-inducing alternative regimen where possible, or — if a strong inducer is unavoidable — increase the TKI dose with monitoring to maintain adequate exposure
C) Reduce the TKI dose during rifampin therapy to avoid accumulation and toxicity
D) Stop the TKI entirely for the full duration of tuberculosis treatment, since the two drugs can never be co-administered
ANSWER: B
Rationale:
Option B is correct. Rifampin strongly induces CYP3A4 and substantially lowers the exposure of a CYP3A4-substrate TKI, risking loss of cancer control. The appropriate, integrated approach is to coordinate with infectious disease to use a non-inducing alternative regimen when possible, or — if a strong inducer is genuinely unavoidable — increase the TKI dose with exposure monitoring to compensate for the induced clearance.
Option A: Option A is incorrect. The induction interaction is substantial and clinically important, so making no change risks treatment failure.
Option C: Option C is incorrect. Induction lowers, not raises, the TKI level, so a dose reduction would worsen underexposure — the wrong direction.
Option D: Option D is incorrect. Co-administration is feasible with a non-inducing alternative or dose adjustment and monitoring; stopping the TKI for the whole TB course needlessly risks cancer progression.
24. [CASE 6 — QUESTION 24]
Continuing with the same patient. As her long-term care plan is finalized, the team reviews safety counseling that applies broadly across the BCR-ABL, EGFR, and ALK tyrosine kinase inhibitor families. Which statement correctly captures two of these shared class principles?
A) Live attenuated vaccines are encouraged to boost immunity, and pregnancy is considered safe on these agents
B) No contraception is necessary, and all vaccines including live attenuated ones may be given freely
C) These drugs are safe in pregnancy but require permanent cessation before any vaccination
D) These TKIs are teratogenic, so women of childbearing potential require effective contraception during therapy; and because they impair immune surveillance, live attenuated vaccines are contraindicated while inactivated vaccines such as the annual influenza vaccine are appropriate
ANSWER: D
Rationale:
Option D is correct. Two class-wide safety messages apply across the BCR-ABL, EGFR, and ALK TKIs. First, these agents are teratogenic, so women of childbearing potential require effective contraception during therapy (and for a defined period afterward depending on the specific drug). Second, because the drugs impair immune surveillance, live attenuated vaccines are contraindicated, whereas inactivated vaccines such as the annual influenza vaccine are appropriate and encouraged.
Option A: Option A is incorrect. The opposite is true: live vaccines are contraindicated and pregnancy is unsafe because of teratogenicity.
Option B: Option B is incorrect. Contraception is required because these drugs can harm a fetus, and live attenuated vaccines are contraindicated rather than freely given.
Option C: Option C is incorrect. These drugs are not safe in pregnancy, and inactivated vaccines need not be withheld; it is live vaccines that are contraindicated.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.